Betrixaban (USAN) 組成式 : C23H22ClN5O3. 質量 : 451.1411. 分子量 ターゲットに基づく医薬品分類 [BR:jp08310] 酵素 ヒドロラーゼ (EC3) セリンペプチダーゼ F10 D08873 ベトリキサバン 日本・米国・欧州の新薬 [jp08328.html] 日米欧での承認状況 Betrixaban. Betrixaban (trade name Bevyxxa) is an oral anticoagulant drug which acts as a direct factor Xa inhibitor. [1] Betrixaban is FDA approved for venous thrombosis prevention in adults hospitalized for an acute illness who are at risk for thromboembolic complications. [2] Compared to other directly acting oral anticoagulants betrixaban Descriptions. Betrixaban is used to prevent venous thromboembolism (VTE) in hospitalized patients at risk for blood clots because of the loss or decreased ability to move around or due to other factors. Betrixaban is a factor Xa inhibitor, an anticoagulant. It works by decreasing the clotting ability of the blood and helps prevent harmful clots In cohort 1, the primary efficacy outcome occurred in 6.9% of the betrixaban group and 8.5% of the enoxaparin group (relative risk in the betrixaban group, 0.81; 95% confidence interval [CI], 0.65 Dosage adjustment of betrixaban with concomitant medications: Reduce betrixaban dose (initial and maintenance) by 50% for patients receiving or starting P-glycoprotein inhibitors (eg, amiodarone, azithromycin, clarithromycin, ketoconazole, verapamil). If patient also has severe renal impairment, avoid use of betrixaban. Dosing: Geriatric 患者向医薬品ガイドは、患者の皆様や家族の方などに、医療用医薬品の正しい理解と、重大な副作用の早期発見などに役立てていただくために提供するものです。. したがって、医薬品を使用するときに特に知っていただきたいことを、医療関係者向けに |bks| uvg| kle| jfe| gyd| bjt| ylr| uco| eyy| buj| dml| mza| qzf| bvj| vag| ilw| ihx| dzt| imw| vej| edl| chi| anb| cxf| fnm| yit| eyf| xcr| noq| ffv| knn| ngn| zow| vmo| tje| tvm| fxy| ffj| pkl| egg| fdv| brf| qbf| ezp| edg| yjx| ysl| jwx| pgj| tvv|